Compare Abbott Laboratories (ABT) vs Atomera Incorporated (ATOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Atomera Incorporated — how do they compare? Abbott Laboratories trades at $95.05 (market cap $166.94B), while Atomera Incorporated trades at $6.71 (market cap $284.76M). The key difference: Abbott Laboratories is far larger — about 586.2× Atomera Incorporated's market cap, and Abbott Laboratories pays a 2.63% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ABT | ATOM | |
|---|---|---|
Market Cap | $166.94B | $284.76M |
Sector | Health | Technology |
52-Week High | $136.62 | $12.11 |
52-Week Low | $82.57 | $1.99 |
Enterprise Value | $193.69B | $244.97M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ATOM trades at $7.355, down 0.74% with bearish technical signals. The company shows severe financial distress with negative gross margins of -520.83% and net losses of -$20.17 million in 2025. Recent earnings misses and negative cash flow highlight operational challenges despite 100% analyst buy ratings. Technical indicators show bearish momentum with support at $7 and resistance at $8.
The outlook remains highly speculative given extreme financial losses and negative cash flow. Investment opportunity hinges on successful commercialization of GaN semiconductor technology, while risks include continued cash burn and failure to achieve revenue growth. The stock represents a high-risk bet on unproven technology execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →
